# Lengo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lengo-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.lengotx.com
- Total disclosed funding: $18M
- Latest round: Series A (Apr 30, 2021)
- Investors on record: 1

## About

Based in California, US, and founded in 2020 by Tracy Saxton, Lengo Therapeutics, Inc. operates as a biopharmaceutical company that develops and provides precision therapies for lung cancer patients. Its CEO is Enoch Kariuki. In November 2021, Blueprint Medicines Corporation, a portfolio company of BVF Partners, Cowen Investment Management, Perceptive Advisors, Sabby Capital, and Wellington Management, agreed to acquire Lengo Therapeutics, Inc. for USD 250 million in cash and an additional USD 215 million upon achieving milestones. 

Lengo Therapeutics, Inc. develops small-molecule precision therapeutics that target driver mutations in oncology. Its focus is on developing inhibitors of protein kinases with mutations known as EGFR exon 20 insertions, which are associated with poor prognoses in non-small cell lung cancer and other solid tumors.

## Funding rounds

- Series A, Apr 30, 2021, $13M — Frazier Healthcare Partners
- Series A, Mar 26, 2020, $4.4M — Frazier Healthcare Partners

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A